IceCure Enrolls First Patients in Its FDA-Approved Study for ProSense® Breast Cancer Cryoablation at Two U.S. Sites
IceCure Medical enrolled the first two patients in its FDA-cleared post-marketing ChoICE Study of ProSense® cryoablation for low-risk breast cancer, at sites in Tennessee and California. The study aims to enroll roughly 400 patients across up to 30 U.S. sites, with participating centers also serving as commercial sites for ProSense®.
Key figures
- Drug Name
- ProSense®
- Phase Of Trial
- post-marketing study (ChoICE Study)
- Planned sites
- up to 30 U.S. clinical sites
- Planned enrollment
- approximately 400 patients
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.